Mandatory registration for Indian clinical trials

By Gareth Macdonald

- Last updated on GMT

Related tags Clinical trials Contract research organization India

From June onwards drug firms and CROs conducting trials in India are required to record full details of the research, including the funding source, on the ICMR’s Clinical Trials Registry India website.

Surinder Singh, drugs controller general of India (DCGI), told Livemint​ that: “Until now, clinical trials were being registered on the website of the Indian Council of Medical Research (ICMR) voluntarily. From January, it was made advisory. But by June, we will make it mandatory​.”

Last August the Indian trials sector was rocked by the revelation that 49 infants have died during clinical trials at the All India Institute of Medical Sciences (AIIMS) in New Delhi since January 2006.

While subsequent investigation showed that the mortality rate was below the national average and did not link the deaths to the drugs under assessment, the scandal led some members of the Indian congress to call for a halt on all trials.

The issue was compounded in October when news emerged that an infant had died after during a trial of a pneumonia vaccine being developed by US drugmaker Wyeth Pharmaceuticals.

In fact, according to contract research organisation (CRO) GVK Biosciences who conducted the trial on Wyeth's behalf, the child had received a reference product rather than the candidate vaccine.

However, a DCGI audit found that the child should never have been enrolled in the trial due to an existing heart condition. This later revelation only intensified pressure for greater regulation.

Patient safety issues aside, the DCGI’s registration decision may also be designed to protect the reputation of the Indian trials sector as a whole, particularly among multinational drug firms thinking of outsourcing research to the country.

According to data gathered by the Indian Government’s Planning Commission, outsourced trials were worth some $300m (€229m) in 2008, up a 65 per cent on 2006. The commission estimates that the sector will be worth $1bn a year by 2010.

As a result, starting on June 1, study sponsors and partner CROs must supply information on the trial, the source of funding and details of an ethics committee that will monitor the study all before the first patient is enrolled.

Unethical trial firms face 10 years in prison

In related news, India’s Economic Times​ reports that under a proposed law change, those convicted of carrying out unethical trials as defined by new DCGI guidelines could face ten years in prison and revocation of their trial licenses.

Vishwa Mohan, from the ICMR, told the paper that the “guidelines would ensure that those who do not follow the norms approved by the DCGI for conducting clinical trials on humans are brought to book and punished​.”

The guidelines, which have been cleared by India’s Health and Legal ministries, require that study subjects are made fully aware of any potential risk involved in participating.

They also require that those recruited for trials meet specific eligibility criteria for participation, with a great emphasis on the health of any potential subject.

Related news

Related products

show more

Unlock potential in buffer preparation

Unlock potential in buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 18-Sep-2023 | Infographic

Consider how the right partner can help you scale faster, mitigate risks, and optimize resources.

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 14-Aug-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Automated metadata management in clinical trials

Automated metadata management in clinical trials

Content provided by Formedix | 01-Aug-2023 | White Paper

When it comes to efficient clinical study build, content is king. Most importantly: metadata content. In this blog, we explore the role of metadata in...

Small Molecule development – getting it right

Small Molecule development – getting it right

Content provided by Lonza Small Molecules | 20-Jun-2023 | Insight Guide

Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can...

Related suppliers

Follow us


View more